Kozakowska et al. found that patients with bladder cancer who had higher serum levels of Nrf2 and its downstream target, HO-1, also had higher serum and tumor levels of VEGF than patients with lower levels of serum Nrf2. The gene discussed is HMOX1; the disease is neoplasm.